Sucampo Pharmaceuticals, Inc. (SCMP)

[surf1944]

6:46AM Sucampo Pharma to present data on AMITIZA (lubiprostone) in opioid-induced constipation at 24th Annual AAPM Meeting; presentation demonstrates that AMITIZA does not affect opioid-induced analgesia, was well-tolerated, and resulted in overall improvement in symptoms in OIC patients (SCMP) 6.20 : Co announced the poster presentation of data evaluating the long-term safety of AMITIZA (lubiprostone) as a treatment for adults with chronic, non-cancer pain suffering from opioid-induced constipation (OIC). This poster presentation demonstrates that AMITIZA does not affect opioid-induced analgesia, was well-tolerated, and resulted in overall improvement in symptoms in OIC patients. Sucampo will present this data at the 24th Annual Clinical Meeting for the American Academy of Pain Management (AAPM) in Orlando, Florida on Friday, September 27, 2013.